MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Antidepressants"

  • MDS Virtual Congress 2021

    Predictors of antidepressant and benzodiazepine treatment in Parkinson’s disease

    G. Gentile, G. Zanotelli, L. Weis, R. Biundo, F. Sambataro, A. Antonini (Padua, Italy)

    Objective: To assess the prevalence of antidepressant and benzodiazepine (BDZ) treatment in Parkinson’s disease (PD), to analyze treatment with respect to altered mood indication, and…
  • MDS Virtual Congress 2021

    Acute functional movement disorder in a Lupus patient

    D. Rebolledo, J. Diestel, I. Reyes (Mexico City, Mexico)

    Objective: Movement disorders (MD) in autoimmune diseases are uncommon. However, the initial presentation required that the clinicians characterize the clinical phenomenology. Rheumatological patients' complexity required…
  • MDS Virtual Congress 2020

    hUC-MSCs ameliorated CUMS-induced depression by modulating complement C3 signaling-mediated microglial polarization during astrocyte-microglia crosstalk

    J. Li, H.L Wang, M.W Wang (Shijiazhuang, China)

    Objective: To demonstrate whether hUC-MSCs can benefit depressive-like behavior by altering C3/C3a-C3aR signaling to impact microglia polarization in the CUMS model. Background: Major depressive disorder (MDD) has been…
  • MDS Virtual Congress 2020

    Elevated nigral iron is associated with low plasma serotonin in Parkinson’s disease

    L. Jellen, A. Snyder, G. Du, M. Lewis, E. Wang, C. Capan, P. Brundin, L. Brundin, J. Connor, X. Huang (Hershey, PA, USA)

    Objective: The objective of this work was to determine whether plasma serotonin levels in Parkinson’s disease (PD) are related to iron levels in the brain,…
  • MDS Virtual Congress 2020

    Effects of Long-Term Treatment with Fluvoxamine on Non-Motor Symptoms and Neurogenesis in an Early Post-Natal Stress Rat Model of Parkinson’s Disease

    E. Dalle, W. Daniels, M. Mabandla (Durban, South Africa)

    Objective: To look at the long-term effects of Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), and its neuroprotection potential in a rat model of Parkinson’s…
  • 2019 International Congress

    Vortioxetine treatment of depression in Parkinson’s disease

    M. Russo, C. Carrarini, F. Dono, L. Ferri, M. Di Pietro, M. Onofrj (Chieti, Italy)

    Objective: To assess efficacy and safety of Vortioxetine in Parkinson’s Disease (PD) patients affected by depression and its effects on motor performance. Background: Depression is…
  • 2019 International Congress

    Predictive Factors for Depression in a Multicentric Parkinson’s Disease Mexican Cohort

    A. Banegas-Lagos, A. Cervantes-Arriaga, D. Garza-Brambila, E. Garcia-Berlanga, K. Salinas-Barboza, S. Isais-Millan, A. Anaya-Escamilla, E. Velazquez-Avila, G. Parra, A. Gonzalez-Cantú, M. Rodriguez-Violante, D. Martinez-Ramirez (Monterrey, Mexico)

    Objective: To identify predictive factors for depression in a multicentric Parkinson’s disease (PD) mexican cohort. Background: Depression is a common symptom of PD with a…
  • 2019 International Congress

    Treating Depression in Parkinson’s Disease: a Systematic Literature Review

    C. Farrell, T. Yousaf, M. Politis (London, United Kingdom)

    Objective: To elucidate the most acceptable and effective treatments for the management of depression in Parkinson’s disease (PD) using a systematic review approach. Background: Depression…
  • 2018 International Congress

    Clinical profiles of late-onset psychiatric patients with incidental REM sleep without atonia

    H. Fujishiro, M. Okuda, K. Iwamoto, S. Miyata, Y. Torii, S. Iritani, N. Ozaki (Nagoya, Japan)

    Objective: The clinical profiles of late-onset psychiatric patients exhibiting incidental REM sleep without atonia (RWA), which is a hallmark of REM sleep behavior disorder (RBD)…
  • 2018 International Congress

    Fluvoxamine maleate effects on dopamine signaling in the prefrontal cortex of stressed parkinsonian rats: Implications for learning and memory

    E. Dalle, W. Daniels, M. Mabandla (Durban, South Africa)

    Objective: In the present study, we investigated the effects of reduced DA presence in the PFC on cognitive function and whether treatment with Fluvoxamine maleate…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley